3692:HKEXHansoh Pharmaceutical Group Company Limited Analysis

Hansoh Pharma is trading around HK$34, comfortably above the 20‑day SMA of 36.46 but just under the 50‑day SMA of 35.88, indicating a short‑term pull‑back within a neutral trend. The RSI sits at 36.5, hinting at modest oversold pressure, while a bearish MACD histogram reinforces the near‑term downside bias. However, the stock enjoys a solid support around HK$33.2 and a sizable upside of roughly 37% versus the DCF‑derived fair value of HK$35.0, suggesting valuation room. On the fundamentals side, revenue surged 32% YoY with gross margins near 90% and a profit margin of 37%, underscoring a high‑quality growth engine. The balance sheet is exceptionally strong, boasting HK$31.6 bn in cash against only HK$0.1 bn debt, a low debt‑to‑equity of 0.30, and a payout ratio of 36%, which supports dividend sustainability. Compared with peers, the PE of 31.9 exceeds the industry average of 27.3, but the forward PE of 27.3 narrows that gap, placing the stock in a blend of growth and value territory.
The beta of roughly 0.25 (quote beta 0.55) signals low market sensitivity, yet 30‑day volatility of 26% and a max drawdown near 29% flag moderate price swings. The healthcare specialty sector carries medium regulatory risk, amplified by Chinese market dynamics, while geographic exposure to China adds a medium‑high layer. Overall, the combination of strong cash generation, attractive dividend yield of 1.28%, and a compelling upside potential makes the stock a candidate for accumulation, especially for investors comfortable with moderate volatility and sector‑specific risks.